TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06468618

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DREAMS Program Video and Care Kit
Description: A pediatric, circadian health program comprised of an introductory video to sleep experiences for stem cell transplant recipients, strategies to improve sleep, and a Sleep and Circadian Care Kit which includes ear plugs, a white noise machine, an eye mask, a lightbox, and kit instructions. Actigraph, Fitbit, and tablet will be provided to participant and family.
Study: NCT05620199

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Upfront resection
Description: Resection of the primary tumor
Study: NCT04950010

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training
Description: HIIT is a type of training in which short periods of high-intensity anaerobic exercise (1-4 minutes at 80-95% of VO2peak) are alternated with less intense aerobic recovery periods (1-3 minutes at 50-60% VO2peak). Individually-tailored exercise prescriptions will be developed based upon each participant's baseline maximal graded exercise test (heart rate corresponding with %VO2 peak) and symptom limitation. Sessions will be progressive in nature such that the volume of exercise (i.e., number and intensity of intervals) increases across weeks. Intervals will progress from a heart rate corresponding with 75% VO2peak in Week 1 to 90-95% VO2peak in Weeks 5-8. Sessions will be \~30 minutes in length. Indoor cycling is the primary mode of exercise.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Moderate-Intensity Exercise
Description: Individually-tailored exercise prescriptions will be developed based upon each participant's baseline maximal graded exercise test (heart rate corresponding with %VO2 peak) and symptom limitation. Sessions will be progressive in nature such that the volume of exercise increases across weeks. Indoor cycling is the primary mode of exercise. Sessions will include moderate-intensity cycling that progresses from a heart rate corresponding with 55-60% VO2peak for 30 minutes in Week 1 to 65-70% VO2peak for 45-50 minutes in Weeks 5-8.
Study: NCT05123066

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aquatic Exercises
Description: These 3 sets were the following:~Set 1: warming up exercise as floating exercise 24 Set 2: Standing education/training Set 3: Walking education/training~The exercises will be conducted taking in consideration safety measures as:~1. Each participant will use Noodles to ensure safety.~2. Each participant will train individually to ensure safety and avoid distraction.~3. Each participant will use special swimming suit in case of lack of bowel and/or bladder control.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Land Exercises
Description: All participants were physical therapy intervention according to their level of functional impairment :
Study: NCT05033691

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic surgery
Description: At two month (8 weeks) post Osimertinib start, patients will be randomized into one of the two study arms. Arm A patients will be treated with stereotactic surgery (SRS). In both arms Osimertinib treatment will continue.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Stereotactic surgery
Description: At two month (8 weeks) post Osimertinib start, patients will be randomized into one of the two study arms. Arm A patients will be treated with stereotactic surgery (SRS). In both arms Osimertinib treatment will continue.
Study: NCT05092217

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirelizumab
Description: Tirelizumab: 200 mg, intravenous injection over 60 minutes (Q3W); Tirelizumab should be applied since 2-6 weeks after surgery until confirmed disease progression, death, unacceptable toxicity, withdrawal of consent, investigator decision, or 1 year.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: salvage surgery
Description: Endoscopic nasopharyngectomy for recurrent nasopharyngeal tumor

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: salvage surgery
Description: Endoscopic nasopharyngectomy for recurrent nasopharyngeal tumor
Study: NCT04778319

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: occlusion of tubes
Description: to occlude the fallopian tubes

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: non occlusion of tubes
Description: not to occlude the tubes
Study: NCT05710666

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab deruxtecan (T-DXd) (IV)
Description: Administered as an intravenous (IV) infusion at a dose of 5.4 mg/kg on Day 1 of each 21-day cycle for up to six cycles.
Study: NCT06511921

Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: late biologic therapy
Description: no biologic therapy for perforated Crohn's disease up to 2 to3 months in the post operative period
Study: NCT06551155

Intervention type: DIAGNOSTIC_TEST
Intervention: Vitality and biological activity of peripheral blood mononuclear cells (PBMCs)
Description: Diagnostic test based on the vitality and biological activity of peripheral blood mononuclear cells (PBMCs) tested analyzing approximately 2-5 mL of blood from healthy patients and from osteopenic and osteoporotic (both fractured and non-fractured) patients of both genders

Intervention type: DIAGNOSTIC_TEST
Intervention: Vitality and biological activity of peripheral blood mononuclear cells (PBMCs)
Description: Diagnostic test based on the vitality and biological activity of peripheral blood mononuclear cells (PBMCs) tested analyzing approximately 2-5 mL of blood from healthy patients and from osteopenic and osteoporotic (both fractured and non-fractured) patients of both genders

Intervention type: DIAGNOSTIC_TEST
Intervention: Vitality and biological activity of peripheral blood mononuclear cells (PBMCs)
Description: Diagnostic test based on the vitality and biological activity of peripheral blood mononuclear cells (PBMCs) tested analyzing approximately 2-5 mL of blood from healthy patients and from osteopenic and osteoporotic (both fractured and non-fractured) patients of both genders

Intervention type: DIAGNOSTIC_TEST
Intervention: Vitality and biological activity of peripheral blood mononuclear cells (PBMCs)
Description: Diagnostic test based on the vitality and biological activity of peripheral blood mononuclear cells (PBMCs) tested analyzing approximately 2-5 mL of blood from healthy patients and from osteopenic and osteoporotic (both fractured and non-fractured) patients of both genders
Study: NCT04256915

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy for Insomnia (CBT-I) + Bright Light Therapy
Description: CBT-I consists of 6 weekly sessions of CBT-I (90-min, 3-6 adolescents in each group) with elements that address the behavioural, cognitive and physiological factors perpetuating insomnia, including: psycho-education about sleep and sleep hygiene, stimulus control, sleep restriction, relaxation training, structured worry time, cognitive restructuring (targeting sleep-related dysfunctional cognitions), and relapse prevention.~Participants will additionally undergo daily morning light therapy by wearing Re-timers (a validated portable light emitting device) at home for 30 minutes. Participants will receive constant blue-green light (500 nm, 506 lux).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioural Therapy for Insomnia (CBT-I) + Placebo Light Therapy
Description: CBT-I consists of 6 weekly sessions of CBT-I (90-min, 3-6 adolescents in each group) with elements that address the behavioural, cognitive and physiological factors perpetuating insomnia, including: psycho-education about sleep and sleep hygiene, stimulus control, sleep restriction, relaxation training, structured worry time, cognitive restructuring (targeting sleep-related dysfunctional cognitions), and relapse prevention.~Participants will additionally undergo daily morning light therapy by wearing Re-timers (a validated portable light emitting device) at home for 30 minutes.Participants will receive red-filtered dim light (\<50 lux).
Study: NCT05361590

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lumoral device
Description: The Lumoral treatment -device is a CE-marked antibacterial home-use device for the treatment and prevention of oral diseases caused by bacteria. It is used in combination with a CE-marked mouth rinse called Lumorinse.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lumoral device
Description: The Lumoral treatment -device is a CE-marked antibacterial home-use device for the treatment and prevention of oral diseases caused by bacteria. It is used in combination with a CE-marked mouth rinse called Lumorinse.
Study: NCT05265338

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KC1036
Description: 60mg QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KC1036
Description: 60mg QD
Study: NCT06545708

Intervention type: OTHER
Intervention: Patients
Description: This group consists of children and adolescents between the ages of 5 and 14, diagnosed with self-limited epilepsy with centrotemporal spikes by a medical professional (epileptologist or neurologist), and in the active phase of the disorder.

Intervention type: OTHER
Intervention: Patients
Description: This group consists of children and adolescents between the ages of 5 and 14, diagnosed with self-limited epilepsy with centrotemporal spikes by a medical professional (epileptologist or neurologist), and in the active phase of the disorder.
Study: NCT06505330

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probactiol Baby
Description: Dietary Supplement: Probactiol Mini 6 droplets of Probactiol Mini daily intake for 13 months
Study: NCT05289739

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: Exercise training during intensive cancer treatment. Training mainly consists of age-appropriate and personalized endurance, strength, flexibility, balance/coordination and gait training. Three to five weekly training sessions lasting 30 to 60 minutes each for about eight to ten weeks (depending on the course of the cancer treatment).
Study: NCT06461650

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nicotine cessation program
Description: Participants will complete up to 4 sessions of a nicotine cessation program over either 12-24 weeks if receiving neoadjuvant chemotherapy prior to surgery or over 4-6 weeks if not receiving neoadjuvant chemotherapy prior to surgery. Each session will be 30-60 minutes long. Participants receiving neoadjuvant chemotherapy will also be eligible for nicotine replacement therapy; however, it must be stopped 6 weeks before surgery.
Study: NCT05524805

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BTL-785-7 Treatment
Description: Treatment of wrinkles with the BTL-785-7 applicator to the BTL-785F system.
Study: NCT04868188

Intervention type: OTHER
Intervention: 5 blood samples
Description: 5 blood samples across 3 occasions/sampling windows (Day 1-4, Day 6-9 and Day 11-14) to determine plasma concentrations of voriconazole

Intervention type: GENETIC
Intervention: Determination of CYP2C19 genotype
Description: A single buccal swab to determine the CYP2C19 genotype will be undertaken during the course of ICU stay.
Study: NCT06156774

Intervention type: OTHER
Intervention: Chimeric Antigen Receptor T-cells (CAR-T) therapy
Description: Patients will be treated with CAR-T cell product as per routine clinical practice.
Study: NCT04264806

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Participants will receive subcutaneous (SC) or intravenous (IV) injection of Azacitidine 75 mg/m\^2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Participants will receive subcutaneous (SC) or intravenous (IV) injection of Azacitidine 75 mg/m\^2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cusatuzumab
Description: Participants will receive SC or IV injection of Cusatuzumab 20 mg/kg.
Study: NCT05336747

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Voice lessons
Description: 12 x 60 minute one-on-one vocal training lessons, once weekly in person or over videoconferencing, and additional 60 min per week home training of vocal pitch control using an internet based vocal pitch app.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Voice lessons
Description: 12 x 60 minute one-on-one vocal training lessons, once weekly in person or over videoconferencing, and additional 60 min per week home training of vocal pitch control using an internet based vocal pitch app.
Study: NCT04800601

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation program 1
Description: Both groups will benefit from a conventional rehabilitation treatment including a repetitive walking.~In addition to this conventional rehabilitation, the experimental group will receive an ankle isokinetic program, 5 times a week, for 6 weeks (with a minimum of 25 sessions)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation program 2
Description: Both groups will benefit from a conventional rehabilitation treatment including a repetitive walking.~The control group will have a supplement in conventional rehabilitation equal to the additional time of the experimental group.
Study: NCT05565196

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Birth companions
Description: The intervention will have the following components: 1) Orient facilities and providers to benefits of BC; 2) Develop/update formal standard operating procedures (SOP) for implementing BC and develop plans to implement SOP; 3) Assess data required for implementation and an audit and feedback cycle for tracking coverage; 4) Assess and carry out modest structural changes in facilities to facilitate BC; 5) Use human centered design to develop materials/resources and a means to distinguish/recognize the BC, taking into account common barriers and misconceptions; 6) Prepare providers to integrate BC into care team; 7) Orient ANC clients to BC rationale and selection; 8) Prepare BCs to support women; 9) Iterate model and track intervention/policies.
Study: NCT05319158

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MIT-PB, movement imitation therapy for preterm.
Description: The instant an infant showed CS or PR movements, the therapists (or a therapist and a parent) intervened by gently guiding the infants' limbs so as to maneuver and smoothen their movements, thereby imitating normal GM sequences as closely as possible, adding variability to the movement
Study: NCT06338345

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Therapeutic drug monitoring of beta-lactam
Description: During the 24 first hours after inclusion, 5 blood samples will be collected to mesure plasmatic concentrations of the studied beta-lactam, of creatinin and of albumin

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Therapeutic drug monitoring of beta-lactam
Description: During the 24 first hours after inclusion, 5 blood samples will be collected to mesure plasmatic concentrations of the studied beta-lactam, of creatinin and of albumin

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Therapeutic drug monitoring of beta-lactam
Description: During the 24 first hours after inclusion, 5 blood samples will be collected to mesure plasmatic concentrations of the studied beta-lactam, of creatinin and of albumin
Study: NCT05324748

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Injection with prednisolon

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline solution
Description: 0,9%
Study: NCT05115630

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: Given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine phosphate
Description: Given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: Given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation One Dose
Description: Given by IV
Study: NCT05237570

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Interradicular septum window
Description: In this group, the maxillary sinus will be accessed through a window in the interradicular septum and the membrane will be elevated, carrying out the regeneration of the area to facilitate subsequent implant placement.
Study: NCT05839912

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Excision of clinically detected lymph node metastasis before any systemic therapy
Description: Surgical intervention to remove the clinically detected lymph node metastasis after which physician choice adjuvant systemic therapy is permitted

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Excision of clinically detected lymph node metastasis after neoadjuvant systemic therapy
Description: Surgical intervention to remove the clinically detected lymph node metastasis after physician choice neo adjuvant systemic therapy. Physician choice adjuvant therapy is allowed after surgery
Study: NCT05340465

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darbepoetin Alfa
Description: Infants in groups 2-5 will be started on Darbe 10 mcg/kg/week between 72 and 84 hours after birth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darbepoetin Alfa
Description: Infants in groups 2-5 will be started on Darbe 10 mcg/kg/week between 72 and 84 hours after birth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darbepoetin Alfa
Description: Infants in groups 2-5 will be started on Darbe 10 mcg/kg/week between 72 and 84 hours after birth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darbepoetin Alfa
Description: Infants in groups 2-5 will be started on Darbe 10 mcg/kg/week between 72 and 84 hours after birth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Molecular Weight Iron Dextran
Description: Infants in groups 2 and 3 will be given LMW-ID IV, 10 or 20 mg/kg/dose. They will be re-dosed if ferritin falls below 76. Iron parameters will be checked biweekly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Molecular Weight Iron Dextran
Description: Infants in groups 2 and 3 will be given LMW-ID IV, 10 or 20 mg/kg/dose. They will be re-dosed if ferritin falls below 76. Iron parameters will be checked biweekly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferumoxytol injection
Description: Infants in groups 4 and 5 will be given FMX IV, 10 or 20 mg/kg/dose. They will be re-dosed if ferritin falls below 76. Iron parameters will be checked biweekly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferumoxytol injection
Description: Infants in groups 4 and 5 will be given FMX IV, 10 or 20 mg/kg/dose. They will be re-dosed if ferritin falls below 76. Iron parameters will be checked biweekly.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral iron supplements
Description: Infants in group 1 will receive standard care in the UW NICU with iron started on day 7 if tolerating 100 mL/kg/day enteral feeding. Iron supplements are adjusted every 2 weeks based on ferritin, zinc protoporphyrin to heme ratio and complete blood count (CBC).
Study: NCT04535440

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT05786027

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PDI
Description: A 12-week in-prison peer-driven intervention to increase the uptake of primary HIV prevention strategies (readiness to initiate addiction treatment (MMT or Atlantis), initiation of MMT/Atlantis, retention in MMT/Atlantis; or the use of SSP), and reduce the use of opioids and HIV risk behaviors, in HIV-negative PWID in prison.
Study: NCT05580601

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CIML-NK Cells
Description: The investigational cell product is a cytokine-induced memory-like natural killer cell preparation, derived from the recipient's haploidentical donor's apheresis product. At the time of infusion, the product is comprised of:~* Cytokine-Induced Memory-Like NK cells (CIML-NK cells)~* Human Serum Albumin~* Plasmalyte~The concentration and total cell number of CIML-NK cells in the product will vary based on the recipient body weight and the dose requested.
Study: NCT05044143

Intervention type: OTHER
Intervention: Monitoring the length of the uterine cervix using transvaginal ultrasound
Description: Cervical length is measured with a 7-9 MHz transvaginal probe by trained obstetricians-gynecologists following the same standardized approach (Berghella 2003). Transvaginal CL measurement is largely used in current obstetric practice, and it is considered the 'gold standard' measurement when assessing the uterine cervix. In contrast to transabdominal US, the transvaginal approach is highly reproducible, and measurements are unaffected by maternal obesity, cervical position, and shadowing from fetal parts (Berghella 2003, Hassan 2000, ACOG 2012, Berghella 2012).
Study: NCT05801679

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: Fifteen minutes after ICU arrival, subjects will be administered sugammadex (2 mg/kg assuming a twitch count of 2-4 of 4 or 4mg/kg assuming a twitch count less than 2 of 4) by the anesthesia provider. Five minutes after administration, a quantitative neuromuscular monitor (TetraGraph, Senzime, Uppsala, Sweden) will be applied and the TOF ratio will be recorded.